N/A
Completed N=763
Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel
Spondyloarthrosis
Source: ClinicalTrials.gov NCT04507776 ↗
Enrolled (actual)
763
Serious AEs
—
Results posted
Oct 2021
Primary outcomePrimary: Percentage of Participants With 7 Years Adherence to Etanercept — 60.6 Percentage of participants
Summary
This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With 7 Years Adherence to Etanercept |
60.6 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosed SpA patients
- 18 years of age and older.
- Did not receive previous other biological treatments.
- Patients have at least 1 year on Enbrel.
Exclusion Criteria
- Had previously used another biological treatments.
- Use of etanercept for less than 1 year duration.
Data sourced from ClinicalTrials.gov (NCT04507776). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.